Mobile

A Multi-Center Single Arm Phase II Study of MDX-010 (BMS-734016) Monotherapy in Patients with Previously Treated Unresectable Stage III or IV Melanoma. Revised Protocol 01, incorporating Amendment ...

Mise à jour : Il y a 5 ans
Référence : EUCTR2005-002051-41

A Multi-Center Single Arm Phase II Study of MDX-010 (BMS-734016) Monotherapy in Patients with Previously Treated Unresectable Stage III or IV Melanoma. Revised Protocol 01, incorporating Amendment 02; and Pharmacogenetics Blood Sample Amendment #01, version 1.0 dated 01-Jul-05, Pharmacogenomics Archived Tissue Sample Amendment #03, version 1 dated 29-Mar-06 and Pharmacogenomic Biomarker Sample Amendment #04, version 1 dated 03-Apr-06

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the Best Overall Response Rate (BORR), (as per modified WHO criteria) in patients with previously treated Stage III (unresectable) or Stage IV melanoma receiving ipilimumab.

Critère d'inclusion

  • Melanoma

Liens